Literature DB >> 10537356

Expression of the c-erbB-3/HER-3 and c-erbB-4/HER-4 growth factor receptors and their ligands, neuregulin-1 alpha, neuregulin-1 beta, and betacellulin, in normal endometrium and endometrial cancer.

R Srinivasan1, E Benton, F McCormick, H Thomas, W J Gullick.   

Abstract

The objective of this study was to determine the immunohistochemical expression of the c-erbB-3 and c-erbB-4 growth factor receptors and their principal ligands, the neuregulins and betacellulin, in normal endometrium and determine whether there was evidence of under- or overexpression in endometrial adenocarcinoma. Immunohistochemistry was performed using well-characterized antibodies against each of the five proteins analyzed on formalin-fixed, paraffin-embedded archival material. Forty-three normal endometrial samples (16 proliferative, 19 secretory, and 8 hyperplastic) and 41 endometrial adenocarcinoma cases were analyzed. There was variable expression of the growth factor receptors and the ligands in the two principal phases of the menstrual cycle as well as in endometrial adenocarcinoma. In normal endometrium, the c-erbB-3 receptor was weakly expressed in both phases. The c-erbB-4 receptor and all of the ligands examined, neuregulin alpha, neuregulin beta, and betacellulin, were expressed at significantly higher levels in the secretory as compared with the proliferative phase of the menstrual cycle, suggesting a role for these proteins in endometrial maturation. In endometrial adenocarcinoma, overexpression of c-erbB-3, c-erbB-4, and betacellulin with underexpression of neuregulin a as compared with normal controls was observed. Neuregulin beta expression was not found to be significantly different in the two groups. These results suggest that signaling through the c-erbB-3 and c-erbB-4 receptors and the ligands neuregulin alpha, neuregulin beta, and betacellulin are important in endometrial carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10537356

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  29 in total

Review 1.  ErbB-4: a receptor tyrosine kinase.

Authors:  W Zhou; G Carpenter
Journal:  Inflamm Res       Date:  2002-02       Impact factor: 4.575

2.  miR-193a-3p functions as a tumor suppressor in lung cancer by down-regulating ERBB4.

Authors:  Hongwei Liang; Minghui Liu; Xin Yan; Yong Zhou; Wengong Wang; Xueliang Wang; Zheng Fu; Nan Wang; Suyang Zhang; Yanbo Wang; Ke Zen; Chen-Yu Zhang; Dongxia Hou; Jing Li; Xi Chen
Journal:  J Biol Chem       Date:  2014-11-12       Impact factor: 5.157

3.  The mitogenic potential of heparin-binding epidermal growth factor in the human endometrium is mediated by the epidermal growth factor receptor and is modulated by tumor necrosis factor-alpha.

Authors:  Katya Chobotova; Mary-Elizabeth Muchmore; Janet Carver; Hyung-J Yoo; Sanjiv Manek; William J Gullick; David H Barlow; Helen J Mardon
Journal:  J Clin Endocrinol Metab       Date:  2002-12       Impact factor: 5.958

Review 4.  Rationale and clinical experience with epidermal growth factor receptor inhibitors in gynecologic malignancies.

Authors:  Ami P Vaidya; Aric D Parnes; Michael V Seiden
Journal:  Curr Treat Options Oncol       Date:  2005-03

Review 5.  Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers.

Authors:  Henry D Reyes; Kristina W Thiel; Matthew J Carlson; Xiangbing Meng; Shujie Yang; Jean-Marie Stephan; Kimberly K Leslie
Journal:  Mol Diagn Ther       Date:  2014-04       Impact factor: 4.074

6.  The profile of the epidermal growth factor system in rat endometrium during postpartum involution period.

Authors:  Emel Alan; Narin Liman; Hakan Sağsöz
Journal:  Vet Res Commun       Date:  2015-03-11       Impact factor: 2.459

7.  Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth.

Authors:  Jorma A Määttä; Maria Sundvall; Teemu T Junttila; Liisa Peri; V Jukka O Laine; Jorma Isola; Mikala Egeblad; Klaus Elenius
Journal:  Mol Biol Cell       Date:  2005-10-26       Impact factor: 4.138

8.  Neuregulin-4 is a survival factor for colon epithelial cells both in culture and in vivo.

Authors:  Jessica K Bernard; Sean P McCann; Vrinda Bhardwaj; Mary K Washington; Mark R Frey
Journal:  J Biol Chem       Date:  2012-10-02       Impact factor: 5.157

9.  ERBB4 is over-expressed in human colon cancer and enhances cellular transformation.

Authors:  Christopher S Williams; Jessica K Bernard; Michelle Demory Beckler; Dana Almohazey; Mary Kay Washington; Jesse J Smith; Mark R Frey
Journal:  Carcinogenesis       Date:  2015-04-27       Impact factor: 4.944

10.  ErbB4 promotes cyclooxygenase-2 expression and cell survival in colon epithelial cells.

Authors:  Mark R Frey; Valda C Hilliard; Matthew T Mullane; D Brent Polk
Journal:  Lab Invest       Date:  2010-06-28       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.